The Salk Institute for Biological Studies

Sanford Burnham Prebys Medical Discovery Institute

Icahn School of Medicine at Mount Sinai

Irm LLC

Sanford-burnham Medical Research Institute

Sumit K Chanda

Nicholas David Peter Cosford

Mitchell Dennis Vamos

John A T Young

John M Marlett

Peter Teriete

Lars Pache

Arturo Diaz

Peter M Palese

Adolfo Garcia-Sastre

Jeremy S Caldwell

John B Hogenesch

John Young

Megan Shaw

Silke Stertz

Renate König

Suhaila White

Nicholas David Cosford

John At Young

John AT Young

Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV).

Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy

Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV). Described herein is the use of IAP antagonists in the treatment of human immunodeficiency virus (HIV) in a mammal, alone or in combination with other therapeutic agents used in HIV therapy. In one aspect, provided herein is a method of treating human immunodeficiency virus (HIV) in an individual in need thereof comprising administering a therapeutically effective amount of at least one inhibitor of apoptosis proteins (IAP) antagonist.

This application relates to the modulation of host cell factors required for influenza virus replication. The application relates to compounds, including nucleic acid compounds (such as, e.g., small interfering RNAs (siRNAs)) and small molecules, that target human host cell factors involved in influenza virus replication, and the use of such compounds for modulating influenza virus replication and as antiviral agents. The application also relates to methods of treating an influenza virus infection and methods of treating or preventing a symptom or disease associated with influenza virus infection, comprising administering to a subject a composition comprising a compound, such as a nucleic acid compound (e.g., an siRNA) or small molecule, that targets a human host cell factor involved in influenza virus replication.

Compositions and methods for inhibiting human host factors required for influenza virus replication

This invention provides novel AP-1 modulatory polypeptides. The invention also provides methods for screening modulators of AP-1 transcription factor activities. The methods comprise first screening test agents for modulators of an AP-1-modulatory polypeptide and then further screening the identified modulating agents for modulators of AP-1 transcription factor activities. The invention further provides methods and pharmaceutical compositions for modulating AP-1 transcription factor activities in a cell and for treating diseases and conditions mediated by abnormal cellular proliferation.

Methods and compositions for modulating activator protein 1

Growing community of inventors

La Jolla, CA, United States of America

Sumit K Chanda